Pre-clinical Microbiology—Atypical Organisms

  • Cécile M. Bébéar
Conference paper

Abstract

The in-vitro activity of moxifloxacin was reviewed and compared to other fluoroquinolones, macrolides, and tetracyclines against atypical and intracellular organisms such asMycoplasma, ChlamydiaandLegionella spp. Moxifloxacin at 0.25 µg/mL inhibited 100% of all the mycoplasma strains tested. AllChlamydia pneumoniae strains were inhibited between 0.06 and 1 µg/mL. Moxifloxacin was very effective againstLegionella pneumophilawith a MIC of 0.06 µg/mL. The MBC values of moxifloxacin againstMycoplasma pneumoniaeandChlamydia pneumoniaewere equal to or within one dilution step of the MIC values. Moxifloxacin was effective in eliminatingM. pneumoniaeandC. pneumoniaefrom the lungs of animal models.

Keywords

Chlamydia Trachomatis Minimum Bactericidal Concentration Mycoplasma Pneumoniae Epithelial Line Fluid Ureaplasma Urealyticum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mayaud C (1997) Epidémiologie des infections respiratoires basses de l’adulte – Rôle de Chlamydia pneumoniae et Mycoplasma pneumoniae. La Presse Médicale 26:1248–1253PubMedGoogle Scholar
  2. 2.
    Marston BJ et al. (1997) Incidence of community-acquired pneumonia requiring hospitalization. Archives of Internal Medicine 157:1709–1718PubMedCrossRefGoogle Scholar
  3. 3.
    Pascuals A, Garcia I, Ballesta S, Perea EJ (1999) Uptake and intracellular activity of moxi-floxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrobial Agents and Chemotherapy 43:12–15Google Scholar
  4. 4.
    Andrews J, Honeybourne D, Jevons G, Wise R (1998) Penetration of moxifloxacin into bronchial mucosa, epithelial lining fluid and alveola macrophages following a single 400 mg oral dose. In: 38th International Congress of Antimicrobial Agents and Chemotherapy, 1998, Abstract A29Google Scholar
  5. 5.
    Bébéar CM, Renaudin H, Boudjadja A, Bébéar C (1998) In vitro activity of BAY 12–8039, a new fluoroquinolone against mycoplasmas. Antimicrobial Agents and Chemotherapy 42:703–704PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs E, Dalhoff A, Brunner H (1996) Efficacy of BAY 12–8039 inMycoplasma pneumoniaeinfected guinea pigs. In: 36th International Congress of Antimicrobial Agents and Chemotherapy, New Orleans. 1996, Abstract Fl7Google Scholar
  7. 7.
    Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R (1997) In vitro activity of BAY 12–8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy, 41:101–106PubMedGoogle Scholar
  8. 8.
    Donati M, Rumpianesi F, Pava G, Sambri V, Cevenini R (1997) In vitro activity of BAY 12–8039 against Chlamydia trachomatis and Chlamydia pneumoniae. In: 37th International Congress of Antimicrobial Agents and Chemotherapy, Toronto, 1997, Abstract F142Google Scholar
  9. 9.
    Roblin PM, Hammerschlag MR (1998) In vitro activitiy of a new 8-methoxyquinolone, BAY 12–8039, against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 42:951–952PubMedGoogle Scholar
  10. 10.
    Waterbury K, Wang JJ, Barbiero M, Federici J, Ohlin C, Huguenel ED (1996) Efficacy of BAY 12–8039, a potent new quinolone, in mouse models of typical and atypical respiratory infection. In: 36th International Congress of Antimicrobial Agents and Chemotherapy, New Orleans, 1996, Abstract Fl8Google Scholar
  11. 11.
    Schulin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM (1998), Susceptibilities ofLegionellaspp. to newer antimicrobials in vitro. Antimicrobial Agents and Chemo-therapy 42:1520–1523PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • Cécile M. Bébéar

There are no affiliations available

Personalised recommendations